Literature DB >> 25612672

Pathogenesis of combined high-grade squamous intraepithelial lesion and adenocarcinoma in situ of the uterine cervix: human papillomavirus genotype and methylation status and immunohistochemical study.

Fumi Kawakami1, Shuho Semba, Hiroe Itami, Noriko Oka, Tamotsu Sudo, Yasuhiko Ebina, Chiho Ohbayashi, Yoshiki Mikami, Hiroshi Yokozaki, Tomoo Itoh.   

Abstract

To determine the etiology of combined high-grade squamous intraepithelial lesion (HSIL) and adenocarcinoma in situ (AIS) of the uterine cervix, we examined human papillomavirus (HPV) subtypes, methylation status of the HPV-16 L1 gene, and immunohistochemical staining pattern of Krt7 in 8 cases of combined HSIL and AIS. Overall, 6 (75%) of 8 patients with combined HSIL and AIS were infected by the same subtype of HPV in both HSIL and AIS (cases 1-5, HPV-16; and case 6, HPV-18), whereas 2 (25%) patients showed infection with different subtypes of HPV (case 7, HPV-31 and -18; and case 8, HPV-52 and -16, in HSIL and AIS, respectively). The degrees of methylation at CpG islands within the HPV-16 L1 gene were almost equivalent between HSIL and AIS in cases 1-4, whereas a great difference in CpG methylation patterns between two was seen in only 1 case (case 5). In addition, both patients infected with different subtypes of HPV between HSIL and AIS were positive for Krt7 only within the AIS component. Based on these results, we propose two distinct developmental pathways of combined HSIL and AIS of the uterine cervix, the common pathway and the individual pathway.

Entities:  

Keywords:  adenocarcinoma in situ (AIS); high-grade squamous intraepithelial lesion (HSIL); human papillomavirus (HPV); methylation

Mesh:

Substances:

Year:  2014        PMID: 25612672

Source DB:  PubMed          Journal:  Kobe J Med Sci        ISSN: 0023-2513


  1 in total

1.  Conservative treatment of coexisting microinvasive squamous and adenocarcinoma of the cervix: report of two cases and literature review.

Authors:  Francesco Sopracordevole; Jacopo Di Giuseppe; Silvia Cervo; Monica Buttignol; Giorgio Giorda; Andrea Ciavattini; Vincenzo Canzonieri
Journal:  Onco Targets Ther       Date:  2016-01-27       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.